MedTrace Logo

INvestigating TELmisartin Study

NCT04715763 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2022-07-01

No results posted yet for this study

Summary

This study will enroll 40 inpatients hospitalized for COVID-19 at Queens' Medical Center. Participants will be randomized 1:1 to Telmisartan (80 mg) vs placebo to be administered orally once daily x 21 days.

Conditions

  • Covid19

Interventions

DRUG

Telmisartan Oral Product

Angiotensin Receptor Blocker (ARB) FDA approved for use in hypertension and for cardiovascular risk reduction

DRUG

Placebo

Gelatin capsules filled with an inactive ingredient

Sponsors & Collaborators

  • Queens Medical Center

    collaborator UNKNOWN

  • University of Hawaii

    lead OTHER

Principal Investigators

  • Cecilia M Shikuma · University of Hawaii at Manoa John A Burns School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-04-26
Completion
2022-04-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04715763 on ClinicalTrials.gov